1. Søgaard M, Madsen M, Løkke A, Hilberg O, Sørensen HT, Thomsen RW. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis. 2016; 11:455–65.
2. Said AF, Ewis AA, Omran AA, Magdy ME, Saleeb MF. Prevalence and predictors of chronic obstructive pulmonary disease among high-risk Egyptians. Egypt J Bronchol. 2015; 9:27–33.
3. Honrubia T, García López FJ, Franco N, Mas M, Guevara M, Daguerre M, et al. Noninvasive vs conventional mechanical ventilation in acute respiratory failure: a multicenter, randomized controlled trial. Chest. 2005; 128:3916–24.
4. Ram FS, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2004; (1):CD004104.
5. Rodríguez-Roisin R. COPD exacerbations.5: management. Thorax. 2006; 61:535–44.
6. Thomas R, Brooks T. Common oligosaccharide moieties inhibit the adherence of typical and atypical respiratory pathogens. J Med Microbiol. 2004; 53:833–40.
7. Darien BJ, Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, et al. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock. 1998; 9:274–81.
8. Yildiz-Pekoz A, Ozsoy Y. Inhaled heparin: therapeutic efficacy and recent formulations. J Aerosol Med Pulm Drug Deliv. 2017; 30:143–56.
9. Glas GJ, Muller J, Binnekade JM, Cleffken B, Colpaert K, Dixon B, et al. HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial. Trials. 2014; 15:91.
10. Glas GJ, Serpa Neto A, Horn J, Cochran A, Dixon B, et al. Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis. Ann Intensive Care. 2016; 6:33.
11. Ahmed SM, Athar M. Mechanical ventilation in patients with chronic obstructive pulmonary disease and bronchial asthma. Indian J Anaesth. 2015; 59:589–98.
12. The Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease [Internet]. Fontana: COLD;[updated 2015; cited Oct 24, 2020]. Available from
http://www.goldcopd.org/.
13. Adriance SM, Murphy CV. Prophylaxis and treatment of venous thromboembolism in the critically ill. Int J Crit Illn Inj Sci. 2013; 3:143–51.
14. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care. 2010; 14:R180.
15. Machin D, Campbell MG, Tan SP, Tan SH. Sample Size Tables for Clinical Studies. 3rd ed. Chichester: John Wiley & Sons, Ltd;2009. p. 47–57.
16. Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015; 2015:507151.
17. Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol. 2009; 6:281–9.
18. Törkvist L, Thorlacius H, Sjöqvist U, Bohman L, Lapidus A, Flood L, et al. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther. 1999; 13:1323–8.
19. de Vroege R, van Oeveren W, van Klarenbosch J, Stooker W, Huybregts MA, Hack CE, et al. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg. 2004; 98:1586–94.
20. Dixon B, Opeskin K, Stamaratis G, Nixon I, Yi M, Newcomb AE, et al. Pre-operative heparin reduces pulmonary microvascular fibrin deposition following cardiac surgery. Thromb Res. 2011; 127:e27–30.
21. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med. 1993; 329:90–5.
22. Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res. 2009; 30:249–56.
23. Ghiasi J, Sadeghian M, Emami M, Kiaie BA, Mousavi S. A pilot study of nebulized heparin for prevention of ventilator induced lung injury: comparative effects with an inhaled corticosteroid. Indian J Crit Care Med. 2017; 21:634–639.
24. Shi X, Li H. Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage. Exp Ther Med. 2013; 5:1367–70.
25. Qian Y, Xie H, Tian R, Yu K, Wang R. Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. COPD. 2014; 11:171–6.
26. Kashefi NS, Nahan JI, Dissanaike D. Does a nebulized heparin/N-acetylcysteine protocol improve outcomes in adult smoke inhalation? Plast Reconstr Surg Glob Open. 2014; 2:e165.
27. Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care. 2008; 12:R64.
28. Shute JK, Calzetta L, Cardaci V, di Toro S, Page CP, Cazzola M. Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: a pilot study. Pulm Pharmacol Ther. 2018; 48:88–96.
29. Jaques LB, Mahadoo J, Kavanagh LW. Intrapulmonary heparin. A new procedure for anticoagulant therapy. Lancet. 1976; 2:1157–61.
30. Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT. Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med. 1999; 160:1653–8.
31. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care. 2010; 14:445.
32. Chang C, Zhu H, Shen N, Han X, Chen Y, He B. Utility of the combination of serum highly-sensitive C-reactive protein level at discharge and a risk index in predicting readmission for acute exacerbation of COPD. J Bras Pneumol. 2014; 40:495–503.
33. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017; 175:250–5.
34. Kumar R, Nigam P. C-reactive protein in chronic obstructive pulmonary disease, its correlation with lung function and the role of statin in chronic obstructive pulmonary disease. Int J Sci Study. 2015; 3:168–171.
35. Gupta R, Kaur R, Singh V, Dahiya K, Gupta A, Kumawat M. Serial estimation of serum CRP levels in patients of COPD with acute exacerbation. Glob J Med Public Health. 2012; 1:1–10.
36. Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in critical care research. Am J Respir Crit Care Med. 2019; 200:828–36.
37. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995; 274:1852–7.
38. Palmieri TL. Use of beta-agonists in inhalation injury. J Burn Care Res. 2009; 30:156–9.
39. McSuley DF, Frank JA, Fang X, Matthay MA. Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med. 2004; 32:1470–6.
40. Darien BJ, Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, et al. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock. 1998; 9:274–81.